ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
about
MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerThe emerging molecular machinery and therapeutic targets of metastasisTackling Cancer Stem Cells via Inhibition of EMT Transcription FactorsFighting the force: Potential of homeobox genes for tumor microenvironment regulationGenomic profiling reveals mutational landscape in parathyroid carcinomasZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression.Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5pZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patientsUbiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinomaOrganotypic culture in three dimensions prevents radiation-induced transformation in human lung epithelial cells.miR-340 and ZEB1 negative feedback loop regulates TGF-β- mediated breast cancer progressionZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance.ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process.Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer.Clinicopathological significance of ZEB-1 and E-cadherin proteins in patients with oral cavity squamous cell carcinoma.Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer.HINT2 downregulation promotes colorectal carcinoma migration and metastasis.Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer typesLKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.TRIM37 promotes epithelial‑mesenchymal transition in colorectal cancerDNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells.Cancer Therapeutics Following Newton's Third LawReactive oxygen species mediate oxaliplatin-induced epithelial-mesenchymal transition and invasive potential in colon cancer.KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.Deregulation of the non-coding genome in leukemia.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression.Pharmacological and immunological targeting of tumor mesenchymalization.Biomarkers for EMT and MET in breast cancer: An update.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Progesterone Receptor Signaling in Uterine Myometrial Physiology and Preterm Birth.Roles of Grainyhead-like transcription factors in cancer.ZEB1-regulated inflammatory phenotype in breast cancer cells.FLASH protects ZEB1 from degradation and supports cancer cells' epithelial-to-mesenchymal transition.
P2860
Q26775086-DF22E856-CAC8-4982-9F5D-484C83C3888EQ27022207-25D1C0BD-2876-4BF1-A856-06713F08B2A0Q28079863-7F774535-3124-42F1-8C5B-F60475FA2B2DQ28547302-0915E914-22E3-4223-81BA-ABF68A0E584AQ30360213-E46C85D9-FA37-4EE8-94D1-6D59D987531BQ33671316-B7C4BF41-E77F-4F43-B521-63699C2F3427Q33688593-FA17B6B8-DC9F-46D8-B02A-CFE85F6D58B1Q33815885-D96C9751-DED7-49CF-B0F0-26091BC45E70Q33892569-6A64F7E7-8C3F-4759-A197-77AB2C33F270Q35695410-30BC4315-1974-4878-AD6A-586FAD81FDDFQ36502762-1E4FC7B8-A332-421A-871F-953969AC6D10Q36587552-8A67FEF2-D2A0-4837-A25F-29522B031897Q37189096-09F2B3AE-A011-4FEA-95EB-2D5DD77CDAFBQ37295569-0384D15F-C128-4FD9-8954-C54A376B2377Q37306553-EF6E2548-C9B5-406F-A962-4955AC79A105Q37307458-5AF489E7-8974-45A5-9A05-4DE0CAA5C4E6Q37344504-4E91745F-ECC4-4D5C-9C8E-F77A8858571AQ37427965-1D64C010-B93D-4DD3-B95F-89CEAA58B9B2Q37650107-C9BB2DD5-EE7F-4F08-9AE9-98C93CCE91CEQ37687288-0CDE465C-377C-441F-9B5A-E2DD8968DC17Q37706655-CFC41E89-5D95-4CD2-A6D6-7D4A380E42F4Q38514906-62F558C3-1F52-469A-8BEF-9A258FEEF6CFQ38529063-ED532872-CD04-4C35-B653-C9D6AC6F271EQ38697495-1332A5AC-E233-4310-B287-20EFDBE9959BQ38720774-E6FE4023-2A3B-4153-A5B4-A53DCF873565Q38743845-CBC7FB17-A236-41CC-89B2-57623C5008A7Q38756307-BF9B8D77-6636-493B-ACAC-D945BFC44191Q38763117-EEDF69A6-DDDE-4EC1-BE2C-312F670737EBQ38806322-B3B7814D-717A-49A8-BD0C-90EA553C0D55Q38824095-D4E516B9-6758-46EA-82D8-276F8443AFDFQ38848335-261CCB75-026D-4CA4-8162-0C5A47159A98Q38879975-74D357F1-77A1-4491-851C-9A37249B41F5Q38909048-5D416E7A-DAEA-423C-8F9B-15B9FE4EA758Q39029043-FC65FCFA-8344-4FC9-BFCD-01D74BA8B35CQ39095878-7770CFB4-2169-4826-BF01-2365519B87EEQ39107981-86E339D5-F683-4457-984D-248D502494F3Q39319711-B02DD5C3-BC5A-42AC-8F29-A10180EFE499Q39438840-713D182D-CF3D-4BBB-8279-88249B5CCB0CQ40171088-8F468EFC-48FF-43E5-A251-BB169C113D8DQ40993392-491CC6B5-BF20-4FD7-84A2-B541B924A047
P2860
ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@ast
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@en
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@nl
type
label
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@ast
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@en
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@nl
prefLabel
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@ast
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@en
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@nl
P2860
P3181
P1433
P1476
ZEB1: at the crossroads of epi ...... astasis and therapy resistance
@en
P2093
Yutong Sun
P2860
P304
P3181
P356
10.1080/15384101.2015.1006048
P407
P577
2015-01-01T00:00:00Z